Drug Profile
Research programme: cancer therapeutics - PharmaMar/Seagen
Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Seattle Genetics
- Developer PharmaMar; Seagen
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 Mar 2022 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 08 Oct 2020 Seattle Genetics is now called Seagen